CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 660 enrolled
Drug / intervention
Conventional Interferon +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01280656
NCT01280656N/ACompleted

Retrospective Study to Evaluate the Impact of Using Interferon (Pegylated or Not) in the Treatment of Patients With Chronic Hepatitis C in Brazil (DECISION)

Hoffmann-La Roche·observational·Posted Jan 21, 2011·Updated Nov 29, 2016

In Brief

An observational study evaluating Conventional Interferon, Peginterferon Alfa-2a, and 2 other interventions for Hepatitis C, Chronic. Completed, enrolled 660 participants across 37 sites.

Detailed Summary

This retrospective study will assess the sustained virologic response and the safety of two different interferons (pegylated or conventional) in patients with chronic hepatitis C. Data will be collected for 24 weeks.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesBrazil
Collaborators--

Timeline

N/ACompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedJan 21, 2011
Enrollment StartJan 1, 2010
Primary CompletionNov 1, 2012
Study CompletionJun 1, 2013
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 15.4 years ago

Interventions

Conventional Interferondrug

Conventional interferon according to the standard of care and aligned with the local prescription instructions

Peginterferon Alfa-2adrug

Peginterferon alfa-2a according to the standard of care and aligned with the local prescription instructions

Peginterferon Alfa-2bdrug

Peginterferon alfa-2b according to the standard of care and aligned with the local prescription instructions

Ribavirindrug

Ribavirin according to the standard of care and aligned with the local prescription instructions